A Comparison of Early Side-Effects of Short Course and Long Course Radiotherapy in Rectal Cancer

IF 0.4 Q4 ONCOLOGY

Middle East Journal of Cancer Pub Date : 2020-10-20 DOI:10.30476/MEJC.2020.83111.1133

A. Mosalaei, Majdaddin Rajaei, H. Nasrollahi, Seyed Hasan Hamedi, S. Omidvari, N. Ahmadloo, M. Ansari, M. Mohammadianpanah

{"title":"A Comparison of Early Side-Effects of Short Course and Long Course Radiotherapy in Rectal Cancer","authors":"A. Mosalaei, Majdaddin Rajaei, H. Nasrollahi, Seyed Hasan Hamedi, S. Omidvari, N. Ahmadloo, M. Ansari, M. Mohammadianpanah","doi":"10.30476/MEJC.2020.83111.1133","DOIUrl":null,"url":null,"abstract":"Background: The variety of neoadjuvant treatments concerning rectal cancer has led to acute complications. The present study aimed to evaluate and compare the acute complications of short-term (SC) and long-term (LC) radiotherapy. \nMethods: We studied 100 patients suffering from rectal cancer, who referred to Nemazee Hospital before their surgery, in this cross-sectional study. The patients were divided into two categories: SC (25 grays radiotherapy at 5 fractions in 5 days) and LC (chemo-radiotherapy with a dose of 45-50.4 grays in 25- 28 fraction in 5-6 weeks with concurrent Capecitabine (825 mg / m2) twice daily and five days a week). Subsequently, we evaluated them for acute complications in the SC group 10-14 days after the end of the treatment and in the LC group at intervals of the treatment, the end of it and 2 weeks afterwards. \nResults: In the LC group compared to the SC group, the percentage of patients with grade 1 diarrhea, grade 2 colitis and grade 1 cystitis at the end of the treatment was statistically different (P 0.05). \n Conclusion: this study implied that there were no significant differences regarding severe acute complication between the two groups.","PeriodicalId":44005,"journal":{"name":"Middle East Journal of Cancer","volume":" ","pages":""},"PeriodicalIF":0.4000,"publicationDate":"2020-10-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Middle East Journal of Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30476/MEJC.2020.83111.1133","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The variety of neoadjuvant treatments concerning rectal cancer has led to acute complications. The present study aimed to evaluate and compare the acute complications of short-term (SC) and long-term (LC) radiotherapy. Methods: We studied 100 patients suffering from rectal cancer, who referred to Nemazee Hospital before their surgery, in this cross-sectional study. The patients were divided into two categories: SC (25 grays radiotherapy at 5 fractions in 5 days) and LC (chemo-radiotherapy with a dose of 45-50.4 grays in 25- 28 fraction in 5-6 weeks with concurrent Capecitabine (825 mg / m2) twice daily and five days a week). Subsequently, we evaluated them for acute complications in the SC group 10-14 days after the end of the treatment and in the LC group at intervals of the treatment, the end of it and 2 weeks afterwards. Results: In the LC group compared to the SC group, the percentage of patients with grade 1 diarrhea, grade 2 colitis and grade 1 cystitis at the end of the treatment was statistically different (P 0.05). Conclusion: this study implied that there were no significant differences regarding severe acute complication between the two groups.

查看原文本刊更多论文

癌症短程和长程放射治疗早期副作用的比较

背景:直肠癌的各种新辅助治疗导致了急性并发症。本研究旨在评估和比较短期(SC)和长期(LC)放疗的急性并发症。方法:我们研究了100例直肠癌患者，他们在手术前转介到Nemazee医院，在这个横断面研究。将患者分为两类:SC(25格瑞放疗，5天5次)和LC(化疗，剂量为45-50.4格瑞，25- 28次，5-6周，同时使用卡培他滨(825 mg / m2)，每天2次，每周5天)。随后，我们评估SC组在治疗结束后10-14天的急性并发症，LC组在治疗间隔、治疗结束后和2周后评估急性并发症。结果:LC组治疗结束时1级腹泻、2级结肠炎、1级膀胱炎患者比例与SC组比较，差异有统计学意义(P < 0.05)。结论:本研究提示两组在严重急性并发症方面无显著差异。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Middle East Journal of Cancer ONCOLOGY-

CiteScore

0.80

自引率

0.00%

发文量

审稿时长

12 weeks

期刊介绍： Middle East Journal of Cancer (MEJC) is an international peer-reviewed journal which aims to publish high-quality basic science and clinical research in the field of cancer. This journal will also reflect the current status of research as well as diagnostic and treatment practices in the field of cancer in the Middle East, where cancer is becoming a growing health problem. Lastly, MEJC would like to become a model for regional journals with an international outlook. Accordingly, manuscripts from authors anywhere in the world will be considered for publication. MEJC will be published on a quarterly basis.